Antitubercular drugs: possible role of natural products acting as antituberculosis medication in overcoming drug resistance and drug-induced hepatotoxicity

被引:4
作者
Rana, Harvesh Kumar [1 ,2 ]
Singh, Amit Kumar [1 ,3 ]
Kumar, Ramesh [1 ,4 ]
Pandey, Abhay K. [1 ]
机构
[1] Univ Allahabad, Dept Biochem, Allahabad 211002, Uttar Pradesh, India
[2] Feroze Gandhi Postgrad Coll, Dept Zool, Raebareli 229001, India
[3] BMK Govt Girls Coll, Dept Bot, Balod 491226, Chhattisgarh, India
[4] Cent Univ Punjab, Dept Biochem, Bathinda 151401, Punjab, India
关键词
Tuberculosis; Drug-resistance; Hepatoprotective; Natural products; Liver injury;
D O I
10.1007/s00210-023-02679-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mycobacterium tuberculosis (Mtb) is a pathogenic bacterium which causes tuberculosis (TB). TB control programmes are facing threats from drug resistance. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mtb strains need longer and more expensive treatment with many medications resulting in more adverse effects and decreased chances of treatment outcomes. The World Health Organization (WHO) has emphasised the development of not just new individual anti-TB drugs, but also novel medication regimens as an alternative treatment option for the drug-resistant Mtb strains. Many plants, as well as marine creatures (sponge; Haliclona sp.) and fungi, have been continuously used to treat TB in various traditional treatment systems around the world, providing an almost limitless supply of active components. Natural products, in addition to their anti-mycobacterial action, can be used as adjuvant therapy to increase the efficacy of conventional anti-mycobacterial medications, reduce their side effects, and reverse MDR Mtb strain due to Mycobacterium's genetic flexibility and environmental adaptation. Several natural compounds such as quercetin, ursolic acid, berberine, thymoquinone, curcumin, phloretin, and propolis have shown potential anti-mycobacterial efficacy and are still being explored in preclinical and clinical investigations for confirmation of their efficacy and safety as anti-TB medication. However, more high-level randomized clinical trials are desperately required. The current review provides an overview of drug-resistant TB along with the latest anti-TB medications, drug-induced hepatotoxicity and oxidative stress. Further, the role and mechanisms of action of first and second-line anti-TB drugs and new drugs have been highlighted. Finally, the role of natural compounds as anti-TB medication and hepatoprotectants have been described and their mechanisms discussed.
引用
收藏
页码:1251 / 1273
页数:23
相关论文
共 46 条
  • [31] Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis
    Saito, Zenya
    Kaneko, Yugo
    Kinoshita, Akira
    Kurita, Yusuke
    Odashima, Kyuto
    Horikiri, Tsugumi
    Yoshii, Yutaka
    Seki, Aya
    Seki, Yoshitaka
    Takeda, Hiroshi
    Kuwano, Kazuyoshi
    BMC INFECTIOUS DISEASES, 2016, 16
  • [32] NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients
    Jaramillo-Valverde, Luis
    Levano, Kelly S.
    Tarazona, David D.
    Capristano, Silvia
    Zegarra-Chaponan, Roberto
    Sanchez, Cesar
    Yufra-Picardo, Velia M.
    Tarazona-Santos, Eduardo
    Ugarte-Gil, Cesar
    Guio, Heinner
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2022, 10 (08):
  • [33] Unveiling the therapeutic promise of natural products in alleviating drug-induced liver injury: Present advancements and future prospects
    Singh, Deepti
    Khan, Mohammad Afsar
    Siddique, Hifzur R.
    PHYTOTHERAPY RESEARCH, 2024, 38 (01) : 22 - 41
  • [34] Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis
    Ben Mahmoud, L.
    Ghozzi, H.
    Kamoun, A.
    Hakim, A.
    Hachicha, H.
    Hammami, S.
    Sahnoun, Z.
    Zalila, N.
    Makni, H.
    Zeghal, K.
    PATHOLOGIE BIOLOGIE, 2012, 60 (05): : 324 - 330
  • [35] SLCO1B1 variants and the risk of antituberculosis drug-induced hepatotoxicity: a systematic review and meta-analysis
    Zhu, Min
    Chen, Xinyu
    Hao, Zhuolu
    He, Yiwen
    Han, Bing
    Tang, Shaowen
    PHARMACOGENOMICS, 2023, 24 (18) : 931 - 942
  • [36] NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients
    An, Hui-Ru
    Wu, Xue-Qiong
    Wang, Zhong-Yuan
    Zhang, Jun-Xian
    Liang, Yan
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2012, 39 (06): : 535 - 543
  • [37] Protective effects of natural products against drug-induced nephrotoxicity: A review in recent years
    Gao, Chen
    Liu, Chang
    Chen, Yuwei
    Wang, Qingtao
    Hao, Zhihui
    FOOD AND CHEMICAL TOXICOLOGY, 2021, 153
  • [38] Utility of Liver Biopsy in the Diagnosis and Management of Possible Drug-Induced Liver Injury in Patients Receiving Antituberculosis Therapy: A Retrospective Study
    Gualano, Gina
    Zace, Drieda
    Mosti, Silvia
    Mencarini, Paola
    Musso, Maria
    Libertone, Raffaella
    Cerva, Carlotta
    Goletti, Delia
    Rianda, Alessia
    Del Nonno, Franca
    Falasca, Laura
    Palmieri, Fabrizio
    INFECTIOUS DISEASE REPORTS, 2023, 15 (06) : 735 - 746
  • [39] CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study
    Tang, S. -W.
    Lv, X. -Z.
    Zhang, Y.
    Wu, S. -S.
    Yang, Z. -R.
    Xia, Y. -Y.
    Tu, D. -H.
    Deng, P. -Y.
    Ma, Y.
    Chen, D. -F.
    Zhan, S. -Y.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (05) : 588 - 593
  • [40] Deep learning and natural products for mitigating drug-induced liver injury in HCV, PFIC, PBC, liver fibrosis, neoplasia, and atherosclerosis
    Sharma, Shubh
    Chinnappan, Jayaprakash
    DISCOVER APPLIED SCIENCES, 2025, 7 (05)